MindWalk Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 52% YoY in Q3 2026, driven by U.S. expansion and the first recurring LensAI contract. Pipeline programs advanced, cash position remains strong, and asset-level financing is in progress.
-
Second quarter saw 54% revenue growth and a 94% increase in gross profit, driven by scalable AI-enabled programs and the divestiture of non-core assets. A strong cash position and new asset portfolio structure support continued investment and protect shareholders from dilution.
-
Record Q1 revenue and margin expansion were achieved, with improved operating results and a strengthened balance sheet following the Netherlands divestiture. The rebranding to MindWalk Inc. and focus on AI-driven platforms position the company for scalable growth and new partnerships.
Fiscal Year 2025
-
Record Q4 revenue and margin expansion driven by BioStrand's triple-digit growth and operational efficiency. Major partnerships, AI platform advances, and a strong cash position set the stage for continued growth, with divestiture and rebranding to sharpen focus.
-
Secured a transformative $8–$10 million partnership, achieved 131.8% BioStrand revenue growth, and raised $8.8 million in equity, while maintaining a 97% gross margin in AI. Ongoing EU divestiture and cost-saving AI collaborations are expected to further enhance profitability.
-
Q2 FY2025 revenue was flat year-over-year but up 16% sequentially, with BioStrand achieving record revenue and high gross margins. Strategic moves include relocating HQ to Austin, divesting European wet labs, and focusing on AI-driven platforms for higher growth and profitability.
-
Q1 FY2025 revenue reached CAD 5.3 million, with strong growth at two sites and robust demand for AI-driven antibody discovery. Net loss widened due to increased R&D, but a strong pipeline and strategic licensing position the company for future growth.
Fiscal Year 2024
-
Achieved record revenue for the fifth consecutive quarter, with fiscal 2024 revenue up 19% year-over-year and significant progress in AI-driven drug discovery. Gross margin declined due to expansion, but cash burn was sharply reduced, and the company expects continued above-market growth in fiscal 2025.